Noticias de ARGX_US
Noticias del mercado
Últimas noticias sobre ARGX_US — 353 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically...
Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DMPatient improvements observed as early as Week 4 and sustained through 52 weeksLate-breaking oral presentation on Wednesday, November 11th, 9:15 – 9:30 AM ET October 19, 2026, 8:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, toda
Shares of Forte Biosciences (FBRX) surged nearly 40% in premarket trading Monday after Argenx (ARGX) agreed to acquire the clinical-stage biotech company in an all-cash deal valued at approximately $2.2 billion, giving the immunology specialist a promisin
View the basic ARGX option chain and compare options of argenx SE on Yahoo Finance.
argenx SE (ARGX) stock price, news, quote and history
argenx SE (CEUX:ARGXb) Stock Price & 30 Year Financial Data
For those with celiac disease, even a little bit of gluten can cause damage to the intestine.
View argenx SE Sponsored ADR ARGX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Página 3 de 18